Increasing ornithine decarboxylase activity is another way of prolactin preventing methotrexate-induced apoptosis: crosstalk between ODC and BCL-2.
Prolactin has more than 300 separate functions including affecting mammary growth, differentiation, secretion and anti-apoptosis. In the previous studies, prolactin induced Bcl-2 expression to prevent apoptosis and also provoked the activity of ornithine decarboxylase (ODC). Our previous data showed that ODC overexpression upregulates Bcl-2 and prevents tumor necrosis factor alpha (TNF-alpha)- and methotrexate (MTX)-induced apoptosis. Here, we further investigate whether prolactin prevents MTX-induced apoptosis through inducing ODC activity and the relationship between ODC and Bcl-2 upon prolactin stimulation. Prolactin prevented MTX-induced apoptosis in a dose-dependent manner in HL-60 cells. Following prolactin stimulation, ODC enzyme activity also shows an increase in a dose-dependent manner, expressing its maximum level at 3 h, and rapidly declining thereafter. Prolactin-induced ODC activity is completely blocked by a protein kinase C delta (PKCdelta) inhibitor, rottlerin. However, there are no changes in the expressions of ODC mRNA and protein level after prolactin stimulus. It indicates that prolactin may induce ODC activity through the PCKdelta pathway. Besides, Bcl-2 expresses within 1 h of prolactin treatment and this initiating effect of prolactin is not inhibited by alpha-difluoromethylornithine (DFMO). However, Bcl-2 is further enhanced following prolactin stimulation for 4 h and this enhancement is blocked by DFMO. Bcl-2 has no effect on ODC activity and protein levels, but ODC upregulates Bcl-2, which is inhibited by DFMO. Overall, there are two different forms of prolactin effect, it induces Bcl-2 primarily, and following this it stimulates ODC activity. Consequently induced ODC activity further enhances the expression of Bcl-2. The anti-apoptotic effect of prolactin is diminished by DFMO and recovered by putrescine. Obviously, ODC activity is one basis for the anti-apoptotic mechanisms of prolactin. A Bcl-2 inhibitor, HA14-1, together with DFMO, completely blocks the anti-apoptotic effects of prolactin. These results suggest that increasing ODC activity is another way of prolactin preventing MTX-induced apoptosis and that this induction of ODC activity enhances the expression of Bcl-2 strongly enough to bring about the anti-apoptotic function.
Hsu
P-C
PC
Department of Medicine, Da-Chien General Hospital, Miao-Li, Taiwan, ROC.
Hour
T-C
TC
Liao
Y-F
YF
Hung
Y-C
YC
Liu
C-C
CC
Chang
W-H
WH
Kao
M-C
MC
Tsay
G J
GJ
Hung
H-C
HC
Liu
G-Y
GY
D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D053938:DNA Fragmentation; D004305:Dose-Response Relationship, Drug; D005493:Folic Acid Antagonists / Q000378:metabolism*; D018922:HL-60 Cells; D006801:Humans; D008727:Methotrexate / Q000378:metabolism* / Q000494:pharmacology; D009955:Ornithine Decarboxylase / Q000235:genetics / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism* / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D015854:Up-Regulation; D051020:bcl-X Protein / Q000378:metabolism
C494811:BCL2L1 protein, human; D005493:Folic Acid Antagonists; D019253:Proto-Oncogene Proteins c-bcl-2; D051020:bcl-X Protein; D011388:Prolactin; D009955:Ornithine Decarboxylase; D008727:Methotrexate